¹Ù·Î°¡±â ¸Þ´º
¹Ù·Î°¡±â ¸Þ´º
º»¹®³»¿ë ¹Ù·Î°¡±â
¸ÞÀθ޴º ¹Ù·Î°¡±â
À§ ³í¹®¿¡¼´Â bispecific fusion proteinÀ» ÀÌ¿ëÇÏ¿© tumor cellÀÌ ¹ßÇöÇÏ°í ÀÖ´Â CD47°ú PD-L1À» dual targetingÇÏ¿© tumor evasionÀ» ¸·´Â Àü·«À» º¸¿©ÁÖ¾ú½À´Ï´Ù.
single·Î CD47À̳ª PD-L1À» targetingÇÏ´Â °Í º¸´Ù ÇÔ²² dual targetingÇßÀ» ¶§ innate, adaptive ¸ðµÎ¿¡¼ anti-tumor effect°¡ ³ô¾ÆÁö´Â °ÍÀ» È®ÀÎÇÏ¿´À¸¸ç, dual targetingÀ» ÇÔÀ¸·Î½á tumor¿¡ specificÇÑ T cell response¸¦ Çâ»ó ½Ãų ¼ö ÀÖ´Â DCÀÇ sensing´É·Âµµ ³ô¿©Áشٴ °ÍÀ» È®ÀÎÇÏ¿´½À´Ï´Ù.
»Ó¸¸ ¾Æ´Ï¶ó, DOX¿Í °°Àº chemodrug°ú ÇÔ²² »ç¿ëµÉ ¶§ ½Ã³ÊÁö È¿°ú¸¦ ³¾ ¼ö ÀÖ¾î, tumor immunotherapyÀÇ »õ·Î¿î insight¸¦ Á¦°øÇß´Ù´Â Á¡¿¡ ÀÇÀÇ°¡ ÀÖ´Â ³í¹®À̾ú½À´Ï´Ù.
¿½ÉÈ÷ ÁغñÇؼ Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
-´ÙÁ¤¿Ã¸²
¸µÅ©:https://pubmed.ncbi.nlm.nih.gov/30134171/